Literature DB >> 30190895

Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma.

Ahmad A Tarhini1,2,1,2, Hussein Tawbi3,3, Walter J Storkus2,4,5,6,7,2,4,5,6,7.   

Abstract

Entities:  

Keywords:  T-cells receptor; adjuvant; dasatinib; dendritic cells; immunotherapy; melanoma; tumor microenvironment; tyrosine kinase inhibitors; vaccine

Year:  2016        PMID： 30190895      PMCID： PMC6094598          DOI： 10.2217/mmt-2016-0016

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  17 in total

1.  Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.

Authors:  Anna R Kwilas; Renee N Donahue; Kwong Y Tsang; James W Hodge
Journal:  Cancer Cell Microenviron       Date:  2015

2.  Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.

Authors:  Elise P Salerno; Sofia M Shea; Walter C Olson; Gina R Petroni; Mark E Smolkin; Chantel McSkimming; Kimberly A Chianese-Bullock; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2013-05-09       Impact factor: 6.968

Review 3.  Reversing T-cell Dysfunction and Exhaustion in Cancer.

Authors:  Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

Review 4.  Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials.

Authors:  Ming Chi; Arkadiusz Z Dudek
Journal:  Melanoma Res       Date:  2011-06       Impact factor: 3.599

5.  A phase 2 trial of dasatinib in advanced melanoma.

Authors:  Harriet M Kluger; Arkadiuz Z Dudek; Carrie McCann; Jean Ritacco; Nadine Southard; Lucia B Jilaveanu; Annette Molinaro; Mario Sznol
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

Review 6.  Vascular normalization as an emerging strategy to enhance cancer immunotherapy.

Authors:  Yuhui Huang; Shom Goel; Dan G Duda; Dai Fukumura; Rakesh K Jain
Journal:  Cancer Res       Date:  2013-02-25       Impact factor: 12.701

Review 7.  Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe.

Authors:  Mark Harries; Josep Malvehy; Céleste Lebbe; Louise Heron; Justyna Amelio; Zsolt Szabo; Dirk Schadendorf
Journal:  Eur J Cancer       Date:  2016-04-22       Impact factor: 9.162

Review 8.  Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression.

Authors:  Ying Zhang; Hildegund C J Ertl
Journal:  Front Immunol       Date:  2016-02-10       Impact factor: 7.561

Review 9.  Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy.

Authors:  Maria Libera Ascierto; Ignacio Melero; Paolo Antonio Ascierto
Journal:  Front Oncol       Date:  2015-07-13       Impact factor: 6.244

10.  Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.

Authors:  Devin B Lowe; Anamika Bose; Jennifer L Taylor; Hussein Tawbi; Yan Lin; John M Kirkwood; Walter J Storkus
Journal:  Oncoimmunology       Date:  2014-02-27       Impact factor: 8.110
View more
  1 in total

Review 1.  Oncogenic functions and therapeutic targeting of EphA2 in cancer.

Authors:  Kalin Wilson; Eileen Shiuan; Dana M Brantley-Sieders
Journal:  Oncogene       Date:  2021-03-08       Impact factor: 9.867
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.